If approved, tofersen would be the first treatment to target a genetic cause of ALS, albeit one ... by 25 January, and Biogen will also have to make the case for its drug at an advisory committee ...

VALOR missed the mark in its first readout in 2021, but according to Biogen the dataset has since improved, showing the drug can slow progression of SOD1 ALS to an extent that is "clinically ...

Just four months after Eli Lilly and British biotech Alchemab penned a discovery collaboration, the Big Pharma is licensing ...

Ionis licensed this drug to Biogen, which is responsible for commercializing ... FDA in April 2023 for amyotrophic lateral ...

Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases. A Deep Dive into Biogen's Financials Market Capitalization ...

Biogen's results beat estimates on strength ... January 6, 2025 Denali Therapeutics' ALS drug fails in mid-to-late stage trial Denali Therapeutics said on Monday its experimental drug failed ...

Speaking of Sage, news broke recently of an unsolicited buyout offer of $7.22 a share from Biogen that was rejected. To my mind, this speaks to the promise they see in this drug and the team at ...

TOKYO -- New treatments for ALS are progressing little by little, with companies like U.S.-based Biogen and Japan's Otsuka Pharmaceutical working to give hope to patients of the incurable disease.

TOKYO -- Japanese drugmaker Eisai is overhauling its U.S. operations as the company seeks ways to overcome the hurdles to wide adoption of its flagship Alzheimer's disease treatment. The company ...

Biogen Beats Q1 Earnings Expectations As Two Newcomer Drug Sales Spike, Avoids Tariff Impact Biogen beat Q1 earnings and revenue estimates, raised rare disease drug sales, and cut its 2025 EPS ...